InspireMD announced a 122% year-over-year revenue increase to $3.4 million in Q1 2026, driven by strong demand for its CGuard Prime carotid stent system. The company received FDA approval to start the CGUARDIANS III clinical trial for its next-gen SwitchGuard neuro protection system in TCAR procedures and expects FDA approval for its original CGuard delivery system by Q3 2026. Despite a voluntary recall of the CGuard Prime 135 cm delivery system for technical improvements, InspireMD remains confident in its product enhancements and market growth potential, aiming to expand its addressable market with the upcoming CGuard Prime 80 cm approval in H2 2026.
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
The global data center semiconductor market is projected to grow from $86.8 billion in 2024 to $265.8 billion by 2029, driven by rising demand for AI-powered servers. The power stage segment will dominate due to its critical role in efficient power d...
The data center direct-to-chip cooling market is projected to grow from $3.33 billion in 2026 to $17.31 billion by 2032, at a CAGR of 26.5%. This growth is driven by the need for precise thermal management in advanced computing, especially for edge c...
The global environmental DNA (eDNA) market is projected to expand from $1.63 billion in 2026 to $5.61 billion by 2031, growing at a 10.2% CAGR. This growth is driven by advanced, non-invasive testing methods that detect species through genetic materi...
